To order this 350+ page report, which features 130+ figures
and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Inclusions
§ A detailed review of the overall landscape of
companies developing RNAi therapeutics, including information on phase of
development (marketed, clinical, and preclinical / discovery stage) of pipeline
candidates, target disease indication(s), key therapeutic areas (oncological
disorders, infectious diseases, genetic disorders, ophthalmic diseases,
respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular
disorders, dermatological disorders, and others), type of RNAi molecule (siRNA, miRNA, shRNA,
sshRNA and DNA), target genes, type of delivery system used, route of
administration and special drug designations (if any).
§ A competitiveness analysis of key players
engaged in this domain, evaluating their respective product portfolios, type of
RNAi molecule, target therapeutic areas, company size and year of
establishment.
§ An analysis of completed, ongoing and planned
clinical studies for different types of RNAi molecules. The trials were
analyzed on the basis of various relevant parameters, such as registration
year, current status, phase of development, type of RNAi molecule, regional
distribution of clinical trials and enrolled patient population.
§ An in-depth analysis of the various patents
that have been filed / granted related to RNAi therapeutics, since 2014. The
analysis also highlights the key parameters associated with the patents,
including information on patent type (granted patents, patent applications and
others), publication year, regional applicability, CPC symbols, emerging focus
areas, leading industry / non-industry players (in terms of the number of
patents filed / granted), and patent valuation.
§ An analysis of the various partnerships pertaining
to RNAi therapeutics, which have been established till August 2019, based on
various parameters, such as the type of partnership, year of partnership,
target disease indications, therapeutic area, type of RNAi molecule, financial
details (wherever applicable), focus area of collaboration and most active
players.
§ An analysis of the investments made at various
stages of development in companies engaged in this domain, between 2014-2019,
including seed financing, venture capital financing, IPOs, secondary offerings,
debt financing, grants and other offerings.
§ An analysis of the key promotional strategies
that have been adopted by developers of marketed oligonucleotide therapeutics,
namely Defitelio®, Exondys® and Onpattro®.
§ A review of emerging technology platforms and
delivery systems that are being used for targeted therapeutic delivery,
featuring detailed profiles of technologies.
§ Detailed profiles of drug candidates that are
in the advanced stages of development (phase II/III and above), including information
on their current development status, mechanism of action, route of
administration, affiliated delivery technology, dosage, recent clinical trial
results along with information on their respective developers.
§ An elaborate discussion on the use of miRNA as
a potential biomarker, along with a list of diagnostic kits that are either
available in the market, or likely to be approved in the foreseen future.
The USD 9.2 billion (by
2030) financial opportunity within the RNAi therapeutics market has been analyzed
across the following segments:
§
§
§
§
§
§
§
§
§ siRNA
§ miRNA
§ shRNA
§ sshRNA
§ DNA
§
§
§
§
§
§
§
§
§
§
§
§
§
The
report features inputs from eminent industry stakeholder(s), according to whom
RNAi therapeutics are promising domain of pharmaceutical industry. The report
includes detailed transcripts of discussions held with the following expert(s):
Amotz Shemi (Chief Executive Officer, Silenseed)
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/278/request-sample.html
Key
Questions Answered
§
§
§
§
§
§
§
§
§
§
You may also be
interested in the following titles:
1.
2.
3.
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
